Induced pluripotent stem cell (iPSC)-derived NK cells can be engineered to overexpress this cleavage resistant CD16a, have remarkable efficacy in pre-clinical cancer models, and transitioned to phase-I clinical trial in patients with cancers (e.g., NCT05395052)16. The gene discussed is FCGR3A; the disease is cancer.